staurosporine has been researched along with bortezomib in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Balunas, MJ; Chai, H; Chin, YW; de Blanco, EJ; Deng, Y; Fong, HH; Kardono, LB; Kim, JA; Kinghorn, AD; Lantvit, DD; Pezzuto, JM; Sugiarso, S; Swanson, SM | 1 |
Carcache de Blanco, EJ; Chai, H; Kinghorn, AD; Lantvit, DD; Matthew, S; Ninh, TN; Pan, L; Soejarto, DD; Swanson, SM; Zhang, X | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Cheng, X; Christ, J; Eisenbrand, G; Merz, KH; Muehlbeyer, S; Thommet, A; Vatter, S; Wölfl, S; Zeller, J | 1 |
Abou-Zeid, LA; Ashour, HF; El-Sayed, MA; Selim, KB | 1 |
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
Cheson, BD | 1 |
Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
Aichberger, KJ; Baumgartner, C; Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Kneidinger, M; Mayerhofer, M; Mirkina, I; Peter, B; Pickl, WF; Sillaber, C; Valent, P | 1 |
Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
1 review(s) available for staurosporine and bortezomib
Article | Year |
---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
9 other study(ies) available for staurosporine and bortezomib
Article | Year |
---|---|
Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes.
Topics: Drug Screening Assays, Antitumor; Female; Flavonoids; HT29 Cells; Humans; Hyptis; Indonesia; Molecular Structure; NF-kappa B; Plants, Medicinal; Pyrones; Stereoisomerism; Structure-Activity Relationship | 2009 |
Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.
Topics: Antineoplastic Agents; Apoptosis; Drug Screening Assays, Antitumor; Flavones; HL-60 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Membrane Potentials; Mitochondria; Piper; Vietnam | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Indoles; Oximes; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Solubility; Structure-Activity Relationship | 2017 |
1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Chalcones; Humans; Molecular Structure; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2020 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mast Cells; Mastocytosis, Systemic; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Staurosporine; Transfection | 2009 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |